Early aggressive intra-venous pulse cyclophosphamide therapy for interstitial lung disease in a patient with systemic sclerosis. A case report.
Affiliation
Department of Rheumatology, Beaumont Hospital, Dublin, Republic of Ireland. rohit_peshin@yahoo.comIssue Date
2009-06MeSH
Anti-Inflammatory AgentsAntineoplastic Agents, Alkylating
Cyclophosphamide
Humans
Infusions, Intravenous
Lung Diseases, Interstitial
Male
Middle Aged
Prednisolone
Scleroderma, Systemic
Metadata
Show full item recordCitation
Early aggressive intra-venous pulse cyclophosphamide therapy for interstitial lung disease in a patient with systemic sclerosis. A case report. 2009, 28 Suppl 1:S31-4 Clin. Rheumatol.Journal
Clinical rheumatologyDOI
10.1007/s10067-009-1098-yPubMed ID
19194736Abstract
Interstitial lung disease is an important cause of mortality and morbidity in patients with systemic sclerosis (SSc). There are currently no recommended guidelines for management of these patients. This is probably due to the rarity of this condition, as well as clinical trials with only a small number of cases. There are published case report and case series along with the two main trials, viz. Scleroderma Lung Study and the Fibrosing Alveolitis Study, but again, there is no consensus on treatment protocols. In this report, we present a case of aggressive interstitial lung disease in a patient with SSc, which improved dramatically on treatment with intra-venous cyclophosphamide and high dose prednisolone therapy.Item Type
ArticleLanguage
enISSN
1434-9949ae974a485f413a2113503eed53cd6c53
10.1007/s10067-009-1098-y